TR study of "multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer"
Latest Information Update: 24 Jun 2020
Price :
$35 *
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms TIRUMPH TR
- 22 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 28 Dec 2017 New trial record